Portrai Insights
Insights on data analysis, AI, and the platform we're building at Portrai.
Latest
27 articles
Comprehensive PortrAIgent Visium Analysis
This six-part series demonstrates an end-to-end spatial transcriptomics workflow using the PortrAIgent platform to analyze TNBC and ER+ breast cancer tissues by integrating Visium data with a…
Portrai-
[Sid’s Data Journey - Part 3] Virtual Tissue Pharmacology: Bringing In Silico Drug Testing to a Patient Tissue
From target expression to tissue pharmacology: modeling how radiopharmaceuticals distribute, accumulate, and deliver dose across Sid’s tumor tissue.
[Sid’s Data Journey - Part 2] Beyond Expression: How to Evaluate Drug Targets
Why target expression alone is not enough. We compare coverage, heterogeneity, spatial distribution, and normal-tissue risk in Sid’s tumor.
[Sid’s Data Journey - Part 1] Single-Patient PortraiTARGET: Data-Driven Target Discovery for Personalized Drug Development
How one patient’s longitudinal single-cell and spatial data can be used to identify and prioritize therapeutic targets with PortraiTARGET.
The Spatial Requirement for Digital Twins: Why Virtual Patients Need an ‘Address’
The Virtual Patient Is Coming In October 2025, SOPHiA GENETICS launched an AI-powered digital twin platform — SOPHiA DDM Digital Twins.
The Spatial Anatomy of Immunotherapy Resistance: Why Checkpoint Inhibitors Stall
Immune Cells Are There — So Why Aren't They Working? Immune checkpoint inhibitors (ICIs) have transformed the landscape of oncology.
On-Target Off-Tumor: Recalculating the Therapeutic Index of Drugs Through Spatial Biology
The cruelest paradox in drug development is that the more effective a drug, the stronger its toxicity can be. Take ADCs (antibody-drug conjugates) as an example. ADCs are designed to deliver...
From AACR 2026: Spatial Biology Is No Longer a Variable — It Is a Constant
What I Confirmed in San Diego Last week, I attended the AACR 2026 Annual Meeting. Every year when I attend this conference, I carry one question with me: "Where does spatial biology stand right now?"
Same Target, Different Destiny: The Spatial Pharmacology of ADCs
Knocking on the Same Target — Why Do the Results Differ? Antibody-drug conjugates (ADCs) are the hottest modality in cancer treatment right now.
WRITTEN BY
Portrai's Authors
Capturing and compounding Portrai's insights.
Daeseung Lee
CEO
Physician-scientist who left clinical practice to bring spatial biology into oncology drug discovery
Hongyoon Choi
CTO
Builds the algorithms that turn spatial transcriptomics into actionable target intelligence
Hyung-Jun Im
CSO
Nuclear medicine specialist linking imaging biomarkers to next-generation radiopharmaceuticals
Kwonjoong Na
CMO
Translates platform insights into IND-enabling decisions across oncology programs
Portrai
Official posts from the Portrai team, decoding disease with spatial intelligence